| Product NDC: | 64406-008 |
| Proprietary Name: | TYSABRI |
| Non Proprietary Name: | natalizumab |
| Active Ingredient(s): | 300 mg/15mL & nbsp; natalizumab |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 64406-008 |
| Labeler Name: | Biogen Idec Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | BLA125104 |
| Marketing Category: | BLA |
| Start Marketing Date: | 20041123 |
| Package NDC: | 64406-008-01 |
| Package Description: | 1 VIAL, SINGLE-USE in 1 CARTON (64406-008-01) > 15 mL in 1 VIAL, SINGLE-USE |
| NDC Code | 64406-008-01 |
| Proprietary Name | TYSABRI |
| Package Description | 1 VIAL, SINGLE-USE in 1 CARTON (64406-008-01) > 15 mL in 1 VIAL, SINGLE-USE |
| Product NDC | 64406-008 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | natalizumab |
| Dosage Form Name | INJECTION |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 20041123 |
| Marketing Category Name | BLA |
| Labeler Name | Biogen Idec Inc. |
| Substance Name | NATALIZUMAB |
| Strength Number | 300 |
| Strength Unit | mg/15mL |
| Pharmaceutical Classes | Integrin Receptor Antagonist [EPC],Integrin Receptor Antagonists [MoA] |